检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:李明闯[1] 王瑞娟[1] 陈国[1] 张青松[1] 吴迪[1] 吕晶[1] 霍彦平[1] 殷德涛[2]
机构地区:[1]郑州大学附属郑州中心医院乳腺甲状腺外科,450052 [2]郑州大学第一附属医院甲状腺外科、河南省高等学校临床医学重点学科开放实验室,450052
出 处:《中华内分泌外科杂志》2015年第6期480-483,492,共5页Chinese Journal of Endocrine Surgery
基 金:国家自然科学基金(81372863);郑州市科技领军人才项目(131PLJRC676)
摘 要:目的抑癌基因甲基化具有可逆性,相关药物可逆转甲基化使失活的基因重新表达。本研究观察去甲基化制剂5-氮杂-2’-脱氧胞苷(5-Aza-CdR)对体外培养的人甲状腺癌TPC-1细胞增殖的影响,及5-iza-CdR对KLF4基因mRNA和蛋白表达水平的影响。方法使用不同浓度的5-Aza-CdR处理TPC-1细胞,采用MTF检测5-Aza-CdR对细胞增殖的影响,利用RT-PCR及蛋白质印迹法(Westemblot)方法检测KLF4基因mRNA和蛋白表达的水平。结果5-Aga—CdR作用于TPC-1细胞24、48及72h后,TPC-1细胞增殖受抑制,且在一定范围内抑制率呈浓度和时间依赖性;TPC-1细胞经5-Aza.CdR干预后,KLF4基因mRNA和蛋白表达水平升高,差异有统计学意义(P〈0.05)。结论5-Aza-CdR能抑制TPC-1细胞增殖,其作用可能是通过去甲基化上调抑癌基因KLF4的表达实现,为甲状腺癌的治疗提供了新思路。Objective Methylation of anti-oncogene can be demethylated by related drugs which can help the inactivated gene to express again. This study aims to study the effects of the demethylating agent 5-Aza- 2'-deoxycytidine on the growth of human thyroid papillary cancer cell line TPC-1 and mRNA and protein expres- sion of KLF4. Methods TPC-1 ceils were treated with different concentration of 5-Aza-CdR. MTI" was used to detect the influence of 5-Aza-CdR on cell proliferation. RT-PCR was used to detect mRNA and protein expression levels of KLF4. Results After being treated with 5-Aza-CdR for 24 hours, 48 hours, and 72 hours, the growth of TPC-1 cells was inhibited and the inhibition was in time and concentration depended manner. After treatment with 5-Aza-CdR, mRNA and protein expression levels of KLF4 were increased, and the difference had statistical signifieanee(P 〈0. 05 ). Conclusion 5-Aza-CdR can inhibit the cell viability of TPC-1 cells through upregulat- ing KLF4 expression, which may provide experimental basis for 5-Aza-CdR in treating thyroid cancer.
关 键 词:KLF4基因 去甲基化 5-氮杂-2’-脱氧胞苷 甲状腺癌
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.15